Trials / Completed
CompletedNCT01635907
Dovitinib in Neuroendocrine Tumors
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.
Detailed description
This investigator-initiated study is being conducted to evaluate whether the investigational drug, Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors (advanced malignant pheochromocytoma or paraganglioma). The primary endpoint will be response rate (Complete + Partial Response) determined by RECIST v 1.1. 25 subjects will be enrolled on this study at the University of Pennsylvania.
Conditions
- Advanced Metastatic Paraganglioma
- Advanced Metastatic Pheochromocytoma
- Recurrent Paraganglioma
- Recurrent Pheochromocytoma
- Unresectable Paraganglioma
- Unresectable Pheochromocytoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dovitinib |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2016-03-01
- Completion
- 2016-04-11
- First posted
- 2012-07-10
- Last updated
- 2020-04-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01635907. Inclusion in this directory is not an endorsement.